Nouscom

About Nouscom

Nouscom is a next-generation immunotherapy company focused on developing engineered viral vectored vaccines for the treatment of cancer. Their mission is to generate safe, innovative, and potent cancer immunotherapies that selectively eliminate tumor cells. The company has offices and facilities in Basel, Switzerland, and Rome, Italy.

Products & Services

NOUS-209:An off-the-shelf cancer immunotherapy based on frameshift neoantigens for the treatment of mismatch repair deficient (dMMR)/microsatellite instability (MSI) tumors.

NOUS-PEV:A personalized neoantigen cancer vaccine tailored to individual patient mutanomes for the treatment of solid tumors.

Endovax:A targeted oncolytic virus delivered locally or systemically, armored with selected immune-modulators for use in solid tumors.

Specialties

Cancer immunotherapy Neoantigen-based vaccines Viral vectored genetic vaccines Oncolytic viruses Personalized cancer vaccines

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 82000000 MR: - FA: €75.8 million FAN: 82000000	D: 2024-03-21 FD: 2024-03-21	11 investors
2	RT: Series C T: - FT: Series C	A: 72000000 MR: - FA: €67.5 million ($72 million) FAN: 72000000	D: 2023-11-14 FD: 2023-11-14	10 investors

Series C Latest

2024-03-21

$82.0M

11 investors (Pro only)

Series C 2023-11-14

$72.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

D'Alise

B

Bechter

F

Fakih

L

Leoni

E

Eckhard Niemeier

Chief Business Officer

R

Riccardo Cortese

Co-Founder

View 31 more team members with Pro

Unlock Full Team Directory

Recent News

Nouscom Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised